ArticlePregnancy (Hoboken, N.J.)2026
Impact of a substance use screening program on racial disparities in urine toxicology testing.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate whether implementing a standardized substance use screening program reduced racial disparities in urine toxicology (Utox) testing among delivery admissions. Methods: We conducted a retrospective cohort study of delivery admissions at a single academic center from June 2019 to June 2025. To address known disparities in Utox testing, a standardized iPad-based screening tool using a modified 4Ps screen was implemented February-May 2023. Screening responses triggered protocolized Utox testing based on a predefined algorithm. Clinical and demographic predictors of Utox testing were compared pre- and post-implementation using chi-square and Results: Among 36,656 admissions, 216 (0.59%) underwent Utox testing: 181 (0.80%) pre-implementation and 32 (0.26%) post-implementation. Pre-implementation, Black patients accounted for 26.8% of tests but only 7.0% of the population. Post-implementation, Black patients represented only 6.3% of tests and 6.5% of the population. The testing rate for Black patients declined from 3.2% to 0.5% ( Discussion: Implementation of a standardized substance use screening tool was associated with a significant reduction in racial disparities in Utox testing at delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.